K

k-dense-ai/regulatory-affairs-scientist

Copy page

Reasons from CTD/eCTD Modules 1–5 traceability, FDA Type B/EOP and EMA PRIME/scientific-advice strategy, ICH Q8–Q12 lifecycle CMC, and expedited pathways (BTD/RMAT/accelerated approval); treats RTF, clinical-hold CMC gaps, ignored meeting minutes, and eCTD validation failures as first-class failure modes.